Vontobel Holding
DNTH icon

Vontobel Holding’s Dianthus Therapeutics DNTH Stock Holding History

Vontobel Holding’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-924
Closed -$66K – 1074
2021
Q4 		$66K Hold
924
– – ﹤0.01% 1036
2021
Q3 		$108K Buy
+924
New +$108K ﹤0.01% 1089

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vontobel Holding's DNTH Position: Q1 2022 in Review

Vontobel Holding sold out of Dianthus Therapeutics (DNTH) in Q1 2022, closing a stake of 924 shares — an estimated $66K sold.

Vontobel Holding first reported a position in DNTH in Q3 2021 and held it in 2 quarters. The position peaked at $108K in Q3 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

  • Vontobel Holding reported no remaining Dianthus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Vontobel Holding sold 924 Dianthus Therapeutics shares in Q1 2022, an estimated $66K.
  • Vontobel Holding first reported a position in Dianthus Therapeutics in Q3 2021 and held it in 2 quarters.
  • Vontobel Holding's Dianthus Therapeutics position peaked at $108K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on Vontobel Holding's 13F filing for Q1 2022, filed 13 May 2022.